Zachary Bloomgarden, MD, Editor of The Journal of Diabetes and Clinical Professor in the Dept. of Medicine at the Mount Sinai School of Medicine, discusses screening of various cardiovascular complications of type 2 diabetes and evaluates their cost-effectiveness. Disclosures: Speaker’s Bureau: Merck, NovoNordisk, GSK Advisory Panel: Merck, BMS, Astra Zeneca, Boehringer Ingelheim, Biodel Consultant: Merck, Novartis, Dainippon Sumitomo Pharma America, Forest Laboratories Stock/Shareholder: Covidien, Bard, Novartis, Roche, Stryker